Quiet Engine behind Pharma’s Next Wave of Growth - Part 3 скачать в хорошем качестве

Quiet Engine behind Pharma’s Next Wave of Growth - Part 3

After two decades of double-digit price inflation, the pharmaceutical sector now faces payer push-back, slower prescription growth in high-income countries and a steep fall-off in R&D productivity. In 2023, CDER approved 55 new drugs never before approved or marketed in the U.S., known as “novel” drugs lower than in 2018 high, with 59¹. At the same time, EvaluatePharma projects that medicines worth US $228 billion in 2024 sales will lose exclusivity by 2028, crimping cash flow for internal discovery.² In that context, strategic alliances defined as contractual partnerships in which each party retains its corporate independence have become less of a tactical convenience and more of a core operating model.